Monument Therapeutics
Pharmaceuticals
Early Growth
2021
monumenttx.com
Monument Therapeutics is a stratified medicine company, that has developed novel digital biomarkers to improve neuroscience drug development. The company is initially focused on two indications for which there are no approved treatments: cognitive impairment in schizophrenia and post-operative cognitive dysfunction (“POCD”). The opportunity is therefore to follow therapeutics through from R&D to the market, where the biomarkers would serve as companion diagnostics.
Monument Therapeutics is repurposing drugs in combination with proprietary cognitive stratification tools to identify the patient sub-groups that are most likely to benefit. This contrasts the years of neuroscience drug development that have been plagued by subjective diagnoses and clinical endpoints.